Poster highlights durable disease stabilization lasting beyond treatment completionResults suggest a unique, multimodal mechanism of action that differs from other…
Presentation Includes Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia (AML)HOUSTON, May…
WOBURN, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the…
Additional clinical and real-world data from the industry’s largest and broadest amyloidosis pipeline will advance understanding of underlying mechanisms of…
Oral mucositis, also called "chemo mouth," has emerged as the most significant adverse event in oncology according to a National…
The company is radically redefining the care model for cancer survivorship BOSTON, MA / ACCESSWIRE / May 23, 2024 /…
Organizational redesign on track, trimming residual pandemic infrastructure and reducing 150 positions by year endU.S. FDA Fast Track designation granted…
Data supports expanding use of PulseVet Shock Wave therapy to treat equine EIPH and equine asthma ANN ARBOR, MI /…
SHELTON, CT / ACCESSWIRE / May 23, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical-stage global leader in…
Hamilton, Bermuda, May 23, 2024 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA – May 23, 2024 -- Altamira Therapeutics Ltd. (“Altamira” or the…